CMS to allow Medicaid mental health demonstrations

CMS sent state Medicaid directors an email on Nov. 13 announcing new opportunities to design service delivery systems for treating mental health. The announcement eases previous prohibitions against using Medicaid funding to pay for short-term residential treatment in an institution for mental disease (IMD).

States can now submit waivers for delivery systems for adults with serious mental illness (SMI) and children with serious emotional disturbance (SED). The SMI/SED demonstration could help improve access to mental health services and limit the negative impacts of these conditions, including improving education and employment goals. In 2016, 10.4 million adults in the United States had an SMI, but only 65 percent received mental health services that year.

Medicaid is already the largest payer of behavioral health services in the country, with more than 25 percent of adults with a serious mental illness relying on Medicaid, according to CMS.

“More treatment options for serious mental illness are needed, and that includes more inpatient and residential options,” HHS Secretary Alex Azar said in a statement. “As with the SUD [substance use disorder] waivers, we will strongly emphasize that inpatient treatment is just one part of what needs to be a complete continuum of care, and participating states will be expected to take action to improve community-based mental health care.”

States can pursue mental health services delivery systems through Section 1115 waivers. To date, 17 states have received authority from CMS to pursue similar demonstration projects related to substance use disorders.

States that participate in the SMI/SED demonstration will be required to take “a number of actions to improve community-based mental health care,” CMS stated. Reimbursement for the demonstration is also limited to beneficiaries who are short-term residents in IMDs primarily to receive mental health treatment. The projects must be budget neutral to the federal government.

States are also required to follow other information reporting with actions on achieving milestones and goals of the demonstrations, including data and performance measures.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.